Granted Patent B2

US 12,306,192 · App. 17/592,433 · Granted May 20, 2025

Inventors: Maya Koronyo (Los Angeles, CA); Haoshen Shi (Los Angeles, CA); Yosef Koronyo (Los Angeles, CA); Keith L. Black (Los Angeles, CA)

Assignee: Cedars-Sinai Medical Center

G01N33/6896A61B3/0025A61B3/102A61B3/12G01N2800/2821

Abstract

Claims (46)

1. A method of detecting pericytes, platelet-derived growth factor receptor-β (PDGFR-β), low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), or combinations thereof in a subject in need thereof, the method comprising:

obtaining a live retinal image of a retina of the subject with an imaging device including a microscope and/or a camera; and

detecting a decrease in the amount of pericytes, platelet-derived growth factor receptor-β (PDGFR-β), LDL receptor-related protein-1 (LRP-1), or combinations thereof present in the retina of the subject using a live retinal imaging technique and/or an advanced ophthalmic imaging technique,

wherein the decrease in the amount of pericytes is detected by comparing the obtained retinal image to a control retinal image or the subject's previous retinal image.

2. The method of claim 1 , wherein:

the subject exhibits one or more symptoms of cognitive impairment;

the subject has or is suspected of having mild cognitive impairment (MCI) and/or Alzheimer's disease; and/or

the subject desires a screening regarding mild cognitive impairment (MCI) or Alzheimer's disease.

3. The method of claim 1 , wherein the detecting the decrease in the amount of pericytes, PDGFR-β, LRP-1 or combinations thereof present in the retina of the subject comprises using adaptive optics, optical coherence tomography angiography, color fundus photography, fluorescein fundus imaging, fluorescein angiography, indocyanine green angiography, scanning laser ophthalmoscopy, optical coherence tomography, confocal microscopy, retinal hyperspectral imaging, and/or optical coherence tomography angiography (OCTA).

4. The method of claim 1 , wherein detecting the decrease in the amount of PDGFR-β present in the retina of the subject comprises:

administering a contrast agent to the subject; and

using optical imaging to detect the amount of PDGFR-β present in the retina.

5. The method of claim 1 , wherein the detecting the decrease in the amount of PDGFR-β present in the retina of the subject comprises:

administering a labelled anti-PDGFR-β antibody; and

using optical imaging to detect the amount of PDGFR-β present in the retina.

6. The method of claim 1 , wherein the detecting the decrease in the amount of LRP-1 present in the retina of the subject comprises:

administering a labelled anti-LRP-1 antibody; and

using optical imaging to detect the amount of LRP-1 present in the retina.

7. The method of claim 1 , further comprising detecting an increase in vascular Aβ deposition in the retina of the subject.

8. The method of claim 7 , wherein the detecting an increase in vascular Aβ deposition in the retina of the subject comprises:

administering an anti-Aβ compound; and

using optical imaging to detect the amount of Aβ deposition in the retina.

9. The method of claim 1 , further comprising predicting cognitive decline in the subject based on the detection of the decrease in the amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the retina.

10. The method of claim 1 , further comprising monitoring the subject by repeating the method.

11. A method of monitoring cognitive status of a subject in need thereof, the method comprising:

obtaining first retinal image of a retina of the subject with an imaging device including a microscope and/or a camera;

detecting, in the first retinal image, an amount of pericytes, platelet-derived growth factor receptor-β (PDGFR-β), LDL receptor-related protein-1 (LRP-1), or combinations thereof present in the retina of the subject using a live retinal imaging technique and/or an advanced ophthalmic imaging technique;

obtaining a second retinal image of the retina of the subject with the imaging device, subsequent to the first retinal image;

detecting, in the second retinal image, an amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the retina of the subject using a live retinal imaging technique and/or an advanced ophthalmic imaging technique;

comparing the amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the first retinal image and the second retinal image; and

detecting whether there is a change in the amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the retina.

12. The method of claim 11 , further comprising:

detecting a decrease in the amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the retina; and

administering a mild cognitive impairment (MCI) or Alzheimer's disease therapy.

13. The method of claim 11 , wherein:

the subject exhibits one or more symptoms of cognitive impairment and/or the subject has or is suspected of having mild cognitive impairment (MCI) and/or Alzheimer's disease; and/or

the subject desires a screening regarding mild cognitive impairment (MCI) or Alzheimer's disease.

14. The method of claim 11 , wherein the detecting the amount of pericytes, PDGFR-β, LRP-1, or combinations thereof present in the retina of the subject comprises using adaptive optics, optical coherence tomography angiography, color fundus photography, fluorescein fundus imaging, fluorescein angiography, indocyanine green angiography, scanning laser ophthalmoscopy, optical coherence tomography, confocal microscopy, retinal hyperspectral imaging, and/or optical coherence tomography angiography (OCTA).

15. A method of detecting an alteration in blood-retinal barrier (BRB) cell tight junction in a subject in need thereof, the method comprising:

assaying a biological sample from the subject by contacting the biological sample with an anti-claudin-1 antibody and detecting a decrease in claudin-1, in the biological sample, wherein the decrease in claudin-1 is compared to a control claudin-1 level or compared to the subject's previous claudin-1 level; or

assaying a biological sample from the subject by contacting the biological sample with an anti-phospho-NF-κB antibody and detecting an increase in NF-κB phosphorylation levels, in the biological sample, wherein the increase in NF-κB phosphorylation levels is compared to a control NF-κB phosphorylation level or compared to the subject's previous NF-κB phosphorylation level; or

detecting an increase in retinal vascular leakage level compared to a control level, or compared to the subject's previous retinal vascular leakage level, by administering a fluorophore to the subject; imaging a retina of the subject; and detecting a level of fluorophore leakage from an image of the retina.

16. The method of claim 15 , wherein the subject in need thereof exhibits one or more symptoms of cognitive impairment, is a subject having or suspected of having mild cognitive impairment (MCI), or a subject having or suspected of having Alzheimer's disease.

17. The method of claim 15 , wherein NF-κB phosphorylation is NF-κB p65 phosphorylation.

18. The method of claim 15 , wherein at least one of the decrease in claudin-1, the increase in NF-κB phosphorylation levels, or the increase in retinal vascular leakage level indicates an alteration in BRB cell tight junction.

19. The method of claim 15 , wherein the detected alteration in BRB cell tight junction indicates cognitive impairment and/or cognitive decline in the subject.

Assignments (1)

Continuity (2)

References Cited (32)